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Abstract
Background: Robust Hedgehog (Hh) signaling has been implicated as a common feature of human
prostate cancer and an important stimulus of tumor growth. The role of Hh signaling has been
studied in several xenograft tumor models, however, the role of Hh in tumor development in a
transgenic prostate cancer model has never been examined.
Results: We analyzed expression of Hh pathway components and conserved Hh target genes
along with progenitor cell markers and selected markers of epithelial differentiation during tumor
development in the LADY transgenic mouse model. Tumor development was associated with a
selective increase in Ihh expression. In contrast Shh expression was decreased. Expression of the
Hh target Patched (Ptc) was significantly decreased while Gli1 expression was not significantly
altered. A survey of other relevant genes revealed significant increases in expression of Notch-1
and Nestin together with decreased expression of HNF3a/FoxA1, NPDC-1 and probasin.
Conclusion: Our study shows no evidence for a generalized increase in Hh signaling during tumor
development in the LADY mouse. It does reveal a selective increase in Ihh expression that is
associated with increased expression of progenitor cell markers and decreased expression of
terminal differentiation markers. These data suggest that Ihh expression may be a feature of a
progenitor cell population that is involved in tumor development.
Background
Sonic hedgehog (Shh) is one of three mammalian hedgehog
(Hh) genes [Sonic hedgehog, Desert hedgehog, Indian hedge-
hog]. Each of the Hh genes encodes a secreted signaling
peptide that binds to a membrane bound receptor (Ptc).
Binding of Hh ligand to the Ptc receptor on the target cell
initiates an intracellular signal transduction cascade that
ultimately activates expression of Hh target genes through
the activity of a family of Gli transcription factors [1]. Pre-
vious studies have identified Shh as an important regula-
tor of prostate development [2-7]. Shh is expressed
exclusively in the epithelium of the developing prostate.
Expression is most abundant during prostate ductal bud-
ding and postnatal ductal morphogenesis and diminishes
to a low level in the adult. Ihh is also expressed in the
prostate epithelium. It is expressed at relatively lower lev-
els in the developing prostate but in a distinctive pattern
and, in contrast to Shh, its expression is maintained undi-
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minished in the adult [8]. Shh expressed by the Urogenital
Sinus (UGS) epithelium induces mesenchymal Hh target
gene expression indicating a paracrine mechanism of
action [2-5,7]. Paracrine signaling directly affects mesen-
chymal proliferation [3,7], but also influence epithelial
proliferation and differentiation by paracrine feedback
mechanisms [[4,7,9], manuscript in preparation]. Auto-
crine or juxtacrine signaling is a prominent feature of Hh
actions in development [1] and several lines of evidence
now suggest that autocrine signaling stimulates prostate
epithelial proliferation [6,10].
Recently Hh signaling has been identified as an important
factor in prostate cancer. Paracrine signaling from tumor
cells has been shown to activate Hh target gene expression
in the adjacent stroma and xenograft studies indicate that
paracrine signaling can accelerate tumor growth [9]. In
addition, evidence has been presented suggesting that
autocrine signaling may also occur, particularly in
advanced prostate cancer, and directly drive tumor cell
proliferation [11-13]. These studies have generated con-
siderable interest in understanding the role of Hh signal-
ing in prostatic neoplasia. We report here the first
characterization of Hh signaling in a transgenic mouse
model of prostate cancer.
The LADY tumor is a transgenic mouse model of prostate
cancer in which the large T antigen gene containing the
deletion mutation d1 2005 (removing expression of small
t antigen) is driven from the prostate specific probasin
promoter [14]. As compared to the TRAMP mouse model,
tumors in LADY transgenic mice (Line 12T-7f) develop
and progress through epithelial hyperplasia, reactive stro-
mal hyperplasia, dysplasia and mouse intraepithelial neo-
plasia (mPIN) similar to that observed in human high
grade PIN. Transgene expression is under androgen con-
trol since the probasin promoter is developmentally regu-
lated by androgens [14]. Thus, changes in epithelial cell
architecture occur in all prostatic lobes as early as four
weeks of age and are identified as clusters of cells contain-
ing elongated, hyperchromatic nuclei interspersed among
normal epithelial cells. Reactive stromal proliferation
occurs in parallel with epithelial cell transformation.
These changes are complete by seven to eight weeks and
the resulting tumors progress from lesions resembling
human low-grade PIN with epithelial stratification and
mild nuclear atypia to HGPIN with marked nuclear atypia
by 15 weeks of age. Although rapid tumor growth pre-
cludes maintaining these mice much beyond four
months, micro-invasion and metastases are rarely seen.
Results
The time-course of tumor development in the 12T-7f sub-
line of the LADY transgenic mouse has previously been
described [14]. We performed an analysis of Hh pathway
gene expression in this subline, collecting tissues from
controls and LADY mice at three, six, nine, 12 and 16
weeks. When mice were sacrificed at 16 weeks, there was
noted to be massive enlargement of the coagulating gland
(CG) of the LADY mice as compared to the controls and
histologic examination confirmed the presence of diffuse
hyperplasia, stromal reaction and in situ carcinoma as
previously described (Fig. 1). To examine expression of
the Hh pathway genes during tumor development, we
examined gene expression in the CG at six and 16 weeks,
time points corresponding to an early post-pubertal stage
and to the adult stage of fully developed in situ carci-
noma, respectively.
Shh expression progressively diminished with age in both
LADY and wild type control mice, but Shh expression
trended lower at six weeks and was significantly lower at
16 weeks in the LADY mice. In contrast, Ihh expression
was significantly increased in the LADY mice at both six
and 16 weeks as compared to the WT controls (Fig. 2). To
determine the net effect on Hh signaling, we examined the
expression of the Shh receptor Ptc and the transcription
factor Gli1, direct Hh target genes whose expression serves
as a measure of Hh pathway activation. Ptc expression was
significantly lower in the CG of the LADY mice than in the
WT controls at all time points examined (three, six, nine,
12 and 16 weeks). The differences at six and 16 weeks are
shown (Fig. 2). Similarly, Gli1 expression was also lower
in the CG of the LADY mice although the differences did
not reach statistical significance. Neither Gli2, Gli3 nor
the Hh signaling pathway gene Smo exhibited signifi-
cantly different expression at either six or 16 weeks (Fig. 2
and data not shown). These data indicate an overall
decrease in the level of Hh signaling in the LADY tumor.
However, the dichotomous changes in Hh ligand expres-
sion suggest the possibility of selective activation of Hh
signaling within a particular niche. Accordingly, we exam-
ined the expression of several tissue-specific Hh target
genes. IGFBP-6 is a target of Hh signaling during fetal
prostate development and IGFBP-3 expression is activated
by Hh treatment of the UGSM-2 cell line [[15,16], unpub-
lished observations]. IGFBP-6 expression was decreased at
both six and 16 weeks in the LADY mouse (Fig. 2) while
expression of IGFBP-3 was unchanged (data not shown).
To examine what changes in epithelial proliferation and
differentiation accompany tumor development in the
LADY mouse, we compared epithelial proliferation and
differentiation at six and 16 weeks (Fig. 3). In the WT
mice, Ki67 staining was detected in an occasional nucleus.
In contrast, most of the nuclei in the LADY mice stained
positive for Ki67 at six weeks and this rapid rate of prolif-
eration was maintained at 16-week tumors. Notch-1 has
been identified as a critical regulator of epithelial prolifer-
ation and differentiation during prostate developmentMolecular Cancer 2007, 6:19 http://www.molecular-cancer.com/content/6/1/19
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[17]. Notch-1 expression increased significantly in the six-
week developing tumor, but not in the established 16-
week tumor, suggesting an early role in the dynamics of
epithelial proliferation and differentiation prior to the
appearance of histologic changes. At 16 weeks, there was
significantly increased expression of mRNA for the stem
cell marker Nestin in the tumor and immunohistochemi-
cal staining localized the increased expression to the basal
layer of the epithelium. FoxA1 and FoxA2 are important
regulators of epithelial proliferation and differentiation
during prostate development that exhibit altered patterns
of expression in human prostate cancer [18]. Quantitative
RT-PCR and immunohistochemical staining showed no
change in the expression of FoxA2 (data not shown).
Quantitative RT-PCR showed diminished FoxA1 mRNA
expression that contrasted with increased staining for
FoxA1 protein in the LADY tumor (Fig. 4). Expression of
the differentiation markers Npdc-1 and probasin were sig-
nificantly decreased in the tumor, suggesting an inhibi-
tion of luminal cell differentiation.
Discussion
Several groups have examined the expression of Hh lig-
ands and Hh signaling activity in human prostate cancer
with inconsistent findings. We first reported that robust
Shh expression and Gli1 expression was characteristic of
both the normal adult human prostate as well as benign
prostatic hyperplasia and prostate cancer [9]. Karhadkar
[11] reported that Shh and Ihh were both expressed in
localized prostate cancer and benign tissue but that the
Hh target genes Ptc and Gli1 were expressed only in met-
astatic tumors. Sanchez et al [12] reported findings sug-
gesting a basal level of Shh, Ptc and Gli1 expression in
benign tissue that is variably increased in cancer while
Sheng et al [13]observed increased Ptc expression that was
attributable in part to mutations that dysregulate Hh sig-
nal transduction. These studies have left unresolved the
role of Hh signaling in tumor development and progres-
sion and for this reason an examination of the Hh path-
way in transgenic tumor models may be instructive. The
data reported here clearly shows that a net increase in Hh
signaling, as measured by expression of the conserved Hh
target genes Ptc and Gli1, is not a feature of tumor devel-
opment in the LADY mouse.
An unexpected and provocative finding was that a net
decrease in Hh pathway activity during tumor develop-
ment, as measured by Ptc expression, actually embraced
divergent changes in expression of the two Hh ligands.
Shh expression was decreased while Ihh expression was
dramatically increased. These changes were evident as
early as three weeks of age (data not shown). Shh and Ihh
are highly related ligands which show functional redun-
dancy in their ability to activate the Hh signal transduc-
tion pathway, but Shh and Ihh are expressed in unique
patterns during prostate development. Whereas Shh
expression localizes to the tips of the developing ducts,
Ihh expression localizes to the epithelium of the urethral
lumen and the origin of the developing ducts. Shh is
expressed abundantly during prostate development and
gradually diminishes to a low level in the adult prostate
[4]. In contrast, lower level Ihh expression is maintained
Histological comparison of control CD-1 and LADY tumor Figure 1
Histological comparison of control CD-1 and LADY tumor. A: H&E staining of the CG from normal litter mate B: H&E 
staining of the CG from a LADY tumor at 16 weeks of age.Molecular Cancer 2007, 6:19 http://www.molecular-cancer.com/content/6/1/19
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at a fairly constant level throughout development and in
adulthood [8]. We have observed two other circumstances
where prostate Ihh expression is increased. The first is dur-
ing prostate development in the Shh transgenic null,
where Hh signaling is maintained by a significant increase
in Ihh expression [8]. The second is during castration-
induced involution of the VP, where there is a marked
increase in Ihh expression without a comparable increase
in Shh expression (unpublished observations). Taken
together, these findings suggest that Shh and Ihh are dif-
ferentially regulated and, while exhibiting some degree of
functionally redundancy, may normally play different
roles in prostate growth regulation. Indeed, studies of Hh
signaling in prostate development suggest that Hh signal-
ing exerts a variety of effects, including stimulation of pro-
genitor cell proliferation, regulating ductal epithelial
proliferation and differentiation and ductal morphogene-
sis through a combination of autocrine and paracrine sig-
naling [19]. The respective roles of Shh and Ihh in these
effects remains to be elucidated, but we have been
intrigued to discover that the domain of Ihh expression
coincides with the regions where tissue specific stem cells
appear to be present in relative abundance [20]. Our find-
ing that Ihh expression is increased in response to castra-
tion suggests that Ihh is expressed by a progenitor cell
population and we speculate that increased Ihh expres-
sion in the LADY tumor results from an expansion of that
progenitor cell population during tumor development.
Tumor development in the LADY mouse is associated
with an increased rate of epithelial proliferation at both
six and 16 weeks, increased expression of progenitor cell
markers (Notch-1, Nestin) and decreased expression of
terminal differentiation markers (Npdc-1 and probasin).
Age dependent changes in Hh pathway gene expression Figure 2
Age dependent changes in Hh pathway gene expression. Gene expression at six and 16 weeks of age in the CG of con-
trol CD-1 and LADY positive mice A: Shh, B: Ihh, C: Ptc1, D: Gli1.Molecular Cancer 2007, 6:19 http://www.molecular-cancer.com/content/6/1/19
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Proliferation and associated gene expression in control CD-1 and LADY CG Figure 3
Proliferation and associated gene expression in control CD-1 and LADY CG. 3A: Panels A and B: Ki67 staining in six 
and 16 week CG was limited to a few scattered epithelial cells (A, arrow; B, arrowheads). Panels C and D: Greater than 50% of 
epithelial cells stained positive for Ki67. 3B: Proliferation associated gene expression changes at six and 16 weeks in control 
CD-1 and LADY CG. Panel A: Notch1, B: Nestin. 3C: Nestin staining at six and 16 week in Control and LADY CG Panels A 
and B: Little to no staining at six weeks with a few cells detected at 16 weeks in control CD-1 CG (Arrow = basal-like cell). 
Panels C and D: Increased nestin expression is observed in 16 week prostate tumor. Asteric = epithelial cells.Molecular Cancer 2007, 6:19 http://www.molecular-cancer.com/content/6/1/19
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Differention associated gene expression changes in LADY tumor development Figure 4
Differention associated gene expression changes in LADY tumor development. 4A: Differentiation gene expression 
analysis in control CD-1 and LADY CG at six6 and 16 weeks of age A: Probasin, B: NPDC-1, C: FoxA1. 4B: Foxa1 staining in 
Control and LADY CG. Panels A and B: FoxA1 protein is detected in the epithelial cells of six and 16 week CG. Panels C and 
D: Dysplastic epithelial cells continue to express high levels of Foxa1, asteric denotes areas of normal prostatic tissue.Molecular Cancer 2007, 6:19 http://www.molecular-cancer.com/content/6/1/19
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These findings are consistent with an expansion of pro-
genitor and/or transit amplifying cell populations. FoxA
proteins belong to the forkhead box a (FoxA) superfamily
of transcription factors and are expressed in endoder-
mally-derived tissues [21]. FoxA1 immunoreactivity is
found in epithelial cells of both the developing and adult
prostate [21]. We found that mRNA levels deceased signif-
icantly in the LADY tumor but that staining for FoxA1 pro-
tein was undiminished. Possible mechanisms for these
findings would include increased rates of mRNA turnover
or stabilization of FoxA1 protein stabilization in cells that
do not udergo terminal differention. FoxA2 expression is
prominent in developing bud epithelium during prostate
development but localizes to basal epithelial cells of the
adult periurethral ducts [21]. FoxA2 has been detected in
neuroendocrine small cell carcinomas and high Gleason
grade adenocarcinomas [18], but FoxA2 mRNA expres-
sion was not increased in the LADY tumors,
Conclusion
There is no net increase in Hh signaling during tumor
development in the LADY prostate cancer model. How-
ever, there is a selective and marked increase in Ihh expres-
sion even as Shh expression is decreased. Tumor
development is associated with increased epithelial prolif-
eration, increased expression on progenitor cell markers
and decreased expression of terminal differentiation
markers. Ihh expression may be associated with a progen-
itor cell population that is expanded during tumor devel-
opment.
Methods
Animals
LADY mice, strain 12T-7f in a CD-1 background, were
used for this study. Animals were bred, raised and sacri-
ficed according to University of Wisconsin animal care
and use guidelines. Prostate specific lobes were harvested
at various times and either fixed in 10% formalin for sec-
tioning or flash frozen for RNA isolation.
RNA isolation and Real Time-PCR
RNA was isolated using Qiagen RNeasy kit with on col-
umn DNase treatment as per manufacturer's directions.
Following reverse transcription by standard protocols,
gene expression was quantitated by real time PCR using
Power SYBR Green PCR master mix (Applied Biosystems)
on a BioRad iCycler. Expression was normalized to the
internal control gene glyceraldehydes-3-phosphate dehy-
drogenase (GAPDH) for each gene assayed. Gene specific
primer sequences are as follows:GAPDH: 5'-
AGCCTCGTCCCGTAGACAAAAT-3' and 5'-CCGTGAGTG
GAGTCATACTGGA-3', Shh: 5'-AATGCC
TTGGCCATCTCTGT-3' and 5'GCTCGACCCTCATAGTG-
TAGAGACT-3', Ihh: 5'-CAGCTCACCCCCAACTACAA-3'
and 5'-GAGCTCACCCCCAACTACAA-3', Ptc1: 5'-CTCT-
GGAGCAGATTTCCAAGG-3' and 5'-TGCCGCAGT-
TCTTTTGAATG-3', Gli1: 5'-
GGAAGTCCTATTCACGCCTTGA-3' and 5'CAACCTTCTT-
GCTCACACATG TAAG-3', Igfbp-6: 5'-AGCTCCAGACT-
GAGGTCTTCC-3' and 5'-GAACGACACTGCTGCTTGC-3',
P21: 5'-TTGCACTCTGGTGTCTGAGC-3' and 5'-TCT-
GCGCTTGGAGTGATAGA-3', Notch1: 5'-ACCCACTCT-
GTCTCCCACAC-3' and 5'-
GCTTCCTTGCTACCACAAGC'-3', Nestin: 5'-GGACAG-
GACCAAGAGGAACA-3' and 5'-TCTGGATCCACCTTT-
TCTGG-3', Probasin: 5'-TCATCCTCCTGCTCACACTG-3'
and 5'-AAGGCCCGTCAATCTTCTTT-3', NPDC-1: 5'-
CCTCCGATGAGGAAAATGAA-3' and 5'-CGTGGAAT-
GGTCAAACAGTG-3', FoxA1: 5'-CTCCTTATGGCGCTAC-
CTTG-3' and 5'-AGCACGGGTCTGGAATACAC-3'.
Immunohistochemical analysis
Tissues were fixed in 10% buffered formalin overnight,
followed by transfer to 50% alcohol. The paraffin-embed-
ded tissues were sectioned (5 μm). Sections were depar-
affinized and rehydrated in ethanol solutions. For FoxA1
(goat anti-FoxA1, Santa Cruz) staining, after antigen
unmasking by boiling in 10 mM sodium citrate buffer
(pH 6.0) for 20 min, the sections were treated with 3%
hydrogen peroxide for 5 min. The following detection and
visualization procedures were performed according to
manufacturer's protocol (Vector Laboratories). For Ki67
staining was done at Vanderbilt Immunohistochemistry
Core/Lab, the sections were rehydrated and placed in
heated Target Retrieval Solution (Labvision, Fremont, CA)
for 20 min. Endogenous peroxidase was neutralized with
0.03% hydrogen peroxide followed by a casein-based pro-
tein block (DakoCytomation, Carpinteria, CA) to mini-
mize nonspecific staining. The sections were incubated
with rabbit anti- Ki-67 (Vector Laboratories, Burlingame,
CA) for 30 min. The Dako Envision+ HRP/DAB System
(DakoCytomation) was used to produce localized, visible
staining. Negative control slides were performed without
primary antibodies.
Statistical Methods
Two-Way Analysis of Variance (ANOVA) was used to com-
pare expression levels as a function of age (six vs. 16
weeks), LADY gene [(-) vs (+)] and their interaction. This
was done separately for each of the proteins (Shh, Ihh, Gli
1, Ptc 1, probasin, p21, nestin, NPDC-1, IGFBP-6). The
tenability of the assumptions of ANOVA was assessed
with residual plots. If the assumptions of ANOVA seemed
to be violated, transformations of the response were con-
sidered. If a term in the model was statistically significant,
pair-wise comparisons were obtained and examined for
significance; this corresponds to Fisher's protected Least
Significant Difference (LSD) procedure. P < 0.05 was the
criterion for statistical significance. The analyses were per-
formed with Proc GLM, SAS v.9.1 statistical software (SAS,Publish with BioMed Central    and   every 
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Cary, NC). Results: The natural logarithms of the expres-
sion levels were log-transformed prior to ANOVA in order
to homogenize the variances and better meet the assump-
tions of ANOVA.
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